The purpose of this study is to investigate the use of autologous umbilical cord blood (UCB) mononuclear cells to mitigate hypoxic neurologic injury among infants with high-risk congenital diaphragmatic hernia (CDH).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
3
6×10\^6 mononuclear cells isolated from the patient's own umbilical cord blood per dose. 4 total doses administered intravenously over 7 days.
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Safety as assessed by vital sign monitoring (heart rate)
Time frame: daily for 7 days following the initial infusion
Safety as assessed by vital sign monitoring (systolic blood pressure)
Time frame: daily for 7 days following the initial infusion
Safety as assessed by vital sign monitoring (diastolic blood pressure)
Time frame: daily for 7 days following the initial infusion
Safety as assessed by vital sign monitoring (temperature)
Time frame: daily for 7 days following the initial infusion
Safety as assessed by pulmonary status (indicated by peak inspiratory pressure (PIP))
Time frame: daily for 7 days following the initial infusion
Safety as assessed by pulmonary status (indicated by positive end expiratory pressure (PEEP))
Time frame: daily for 7 days following the initial infusion
Safety as assessed by pulmonary status (indicated by respiratory rate (RR))
Time frame: daily for 7 days following the initial infusion
Safety as assessed by pulmonary status (indicated by Fraction of inspired oxygen (FiO2))
Time frame: daily for 7 days following the initial infusion
Safety as assessed by presence of new infiltrates or altered aeration upon chest radiography
Time frame: daily for 7 days following the initial infusion
Safety as assessed by cardiovascular status (indicated by heart rate)
Time frame: daily for 7 days following the initial infusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Safety as assessed by cardiovascular status (indicated by systolic blood pressure)
Time frame: daily for 7 days following the initial infusion
Safety as assessed by cardiovascular status (indicated by diastolic blood pressure)
Time frame: daily for 7 days following the initial infusion
Safety as assessed by cardiovascular status (indicated by changes in cardiovascular pharmacologic support)
Time frame: daily for 7 days following the initial infusion
Safety as assessed by infection status (indicated by body temperature)
Time frame: daily for 7 days following the initial infusion
Safety as assessed by infection status (indicated by white blood cell count)
Time frame: 7 days following the initial infusion
Safety as assessed by infection status (indicated by physical signs of infection)
Time frame: daily for 7 days following the initial infusion
Safety as assessed by liver function (indicated by Alanine aminotransferase (ALT) levels)
Time frame: 7 days following the initial infusion
Safety as assessed by liver function (indicated by aspartate aminotransferase (AST) levels
Time frame: 7 days following the initial infusion
Safety as assessed by liver function (indicated by bilirubin levels)
Time frame: 7 days following the initial infusion
Safety as assessed by liver function (indicated by albumin levels)
Time frame: 7 days following the initial infusion
Safety as assessed by blood urea nitrogen (BUN) levels
Time frame: 7 days following the initial infusion
Safety as assessed by creatinine levels
Time frame: 7 days following the initial infusion
Safety as assessed by carbon dioxide (CO2) levels
Time frame: 7 days following the initial infusion
Safety as assessed by glucose levels
Time frame: 7 days following the initial infusion
Safety as assessed by serum chloride levels
Time frame: 7 days following the initial infusion
Safety as assessed by serum potassium levels
Time frame: 7 days following the initial infusion
Safety as assessed by serum sodium levels
Time frame: 7 days following the initial infusion
Neurologic/neurodevelopmental status as assessed by intracranial abnormalities upon magnetic resonance imaging (MRI)
Time frame: within 14 days of discharge (discharge occurs at about 2-4 months after birth)
Neurologic/neurodevelopmental status as assessed by receipt of neurologic pharmacologic medications
Time frame: at the time of discharge (which is about 2-4 months after birth)
Neurologic/neurodevelopmental status as assessed by Bayley Scales of Infant and Toddler Development-III (BSID-III)
The Bayley-III is an individually-administered examination that assesses the current developmental functioning of infants and young children from birth to 42 months of age. The Bayley is a standardized, norm-referenced measure that assesses development in Cognitive, Language and Motor domains. Composite standard scores can be derived that have a mean of 100 and a standard deviation of 15.
Time frame: 2 years after birth
Mortality
Time frame: 2 years after birth
Length of stay in hospital
Time frame: from birth to discharge or death, whichever occurs first (discharge occurs at about 2-4 months after birth)
Progression of pulmonary hypertension as assessed by echocardiography
Time frame: within 24 hours of birth, prior to operative repair (occurs between day 2 & 14 of life), prior to discharge (usually 2-6 months), and after discharge (2wks-6 months following discharge)
Duration of extracorporeal membrane oxygenation (ECMO) support
Time frame: days from ECMO initiation until decannulation (an average of 3 weeks)
Duration of ventilatory support
Time frame: from initiation of ventilation until extubation (an average of 8 weeks)